- Home
- INBK vs ELDN Comparison
INBK vs ELDN Comparison
Compare INBK & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBK
- ELDN
- Stock Information
- Founded
- INBK 1999
- ELDN 2004
- Country
- INBK United States
- ELDN United States
- Employees
- INBK N/A
- ELDN N/A
- Industry
- INBK Major Banks
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- INBK Finance
- ELDN Health Care
- Exchange
- INBK Nasdaq
- ELDN Nasdaq
- Market Cap
- INBK 196.2M
- ELDN 178.4M
- IPO Year
- INBK N/A
- ELDN N/A
- Fundamental
- Price
- INBK $23.32
- ELDN $2.72
- Analyst Decision
- INBK Buy
- ELDN Strong Buy
- Analyst Count
- INBK 4
- ELDN 2
- Target Price
- INBK $34.50
- ELDN $12.50
- AVG Volume (30 Days)
- INBK 37.3K
- ELDN 205.3K
- Earning Date
- INBK 07-23-2025
- ELDN 08-18-2025
- Dividend Yield
- INBK 1.03%
- ELDN N/A
- EPS Growth
- INBK 27.37
- ELDN N/A
- EPS
- INBK 2.40
- ELDN N/A
- Revenue
- INBK $114,609,000.00
- ELDN N/A
- Revenue This Year
- INBK $5.36
- ELDN N/A
- Revenue Next Year
- INBK $17.09
- ELDN N/A
- P/E Ratio
- INBK $9.72
- ELDN N/A
- Revenue Growth
- INBK 20.13
- ELDN N/A
- 52 Week Low
- INBK $19.54
- ELDN $2.30
- 52 Week High
- INBK $43.27
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- INBK 46.70
- ELDN 35.43
- Support Level
- INBK $22.46
- ELDN $2.76
- Resistance Level
- INBK $24.67
- ELDN $2.90
- Average True Range (ATR)
- INBK 0.67
- ELDN 0.16
- MACD
- INBK -0.05
- ELDN -0.03
- Stochastic Oscillator
- INBK 38.91
- ELDN 4.39
About INBK First Internet Bancorp
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.